The biotech company's share price climbed on the Paris Bourse on Thursday, following an update on the clinical development program for one of its leading drug candidates.

In a press release, the company reports that it has activated its first clinical trial site in the United States, Next Oncology in San Antonio, for a Phase 1b/2 trial of AsiDNA.

The study is designed to assess the safety and efficacy of this compound in combination with a PARP inhibitor in patients with epithelial ovarian cancer, breast cancer and metastatic castration-resistant prostate cancer (CRPC) who have progressed on previous treatment with PARP inhibitors.

The primary endpoint of the study is to assess the safety and tolerability of the combination and determine the optimal dose for the Phase 2 trial.

At the same time, Onxeo is continuing its Phase 1b/2 study to assess the safety and efficacy of AsiDNATM in combination with PARP inhibitors in patients with relapsed platinum-sensitive ovarian cancer already treated with PARP inhibitors.

The study, sponsored by Gustave Roussy's Cancer Campus, recently completed its first interim analysis on 10 patients.

According to Onxeo, the recent encouraging activity observed in the preliminary data from the study demonstrates AsiDNA's potential to re-sensitize patients to inhibitor therapy.

The company believes this could have a significant impact on patients with recurrent ovarian cancer that has progressed after initial treatment with PARP inhibitors.

Listed on the Paris Bourse, Onxeo shares jumped 11.8% following these announcements, after having climbed over 23% in early morning trading.

Copyright (c) 2023 CercleFinance.com. All rights reserved.